Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).
“I am delighted to welcome George to the Mythic team,” said Brian Fiske, Ph.D., Chief Scientific Officer and Co-Founder at Mythic Therapeutics. “George’s extensive experience in corporate strategy, business development and launching innovative medicines in oncology, coupled with his vision and proven leadership, will be invaluable as we move into our next phase of growth and innovation with our clinical and preclinical ADC candidates.”
Dr. Eliades joins Mythic from Jazz Pharmaceuticals, where he was a member of the executive team, serving as the Senior Vice President of Corporate Development and Chief Transformation Officer. In his 4 years at Jazz Pharmaceuticals, he led the $7.2B acquisition and integration of GW Pharmaceuticals, the acquisition of development and commercial rights for JZP898 and JZP441, two early-stage clinical programs for treating solid tumors and sleep disorders, and the licensing agreement for zanidatamab, an investigational HER2-targeted bispecific antibody. Prior to that, Dr. Eliades spent over 20 years at Bain & Company and Monitor Group, advising biotech clients in corporate strategy, M&A, growth and digital-driven transformations.
Dr. Eliades stated, “I’m incredibly excited to join Mythic and work toward improving outcomes for more cancer patients through our pipeline of innovative ADCs. I look forward to working with the leadership team and employees to accelerate clinical development of the Company’s lead therapeutic candidate, MYTX-011, and continue expanding the application of our platform to develop impactful therapies for patients.”
“This team has made significant strides in developing its pipeline, with a unique focus on the antibody component of the ADC,” said Bryan Roberts, Partner of Venrock and a member of Mythic’s Board of Directors. “Dr. Eliades joins at a critical time where his leadership and wealth of industry experience will be instrumental in building an enduring multi-product oncology company as it continues to expand its ADC-focused pipeline and drive toward transformative outcomes for cancer patients.”
About Mythic Therapeutics
Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl™ technology aims to enhance ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the diseases and patient profiles that could be treated with Mythic’s ADCs. The company’s major investors include Venrock, Viking Global Investors, and First Round Capital.
For more information, visit: www.mythictx.com and follow on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328009665/en/
Contacts
Media Contact:
Media@mythictx.com
